KLSMC Stem Cells Sdn. Bhd., a subsidiary of Kuala Lumpur Sports Medicine Centre, was established in 2005 specifically to spearhead the research on stem cells regenerative therapy in the musculoskeletal system. Following internationally recognized medical research ethics and protocols, a series of studies were undertaken culminating in 2007 with the beginning of the human pilot study.
Several clinical studies led by Dr. Saw Khay Yong (consultant orthopaedic surgeon and CEO) revealed a breakthrough discovery: in injecting the patient’s own blood stem cells, coupled with surgical intervention and physiotherapy, it was possible for patients to regenerate hyaline cartilage.
In early 2010, a US patent (patent no: US 8,377,432 B2: Method and composition for neochondrogenesis) was filed for the stem cell technology and it was granted in 2013.